Although the lack of specificity of FRZB for ALS-related muscle denervation may limit its use for diagnostic purposes, its relative increase in the SOD1G93A mouse over different disease stages suggests that it reflects disease progression in the late pre-symptomatic and symptomatic stages. Here, FRZB is linked to amyotrophic lateral sclerosis.